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Background: Staphylococcal epidermolytic toxins A and B (ETA and ETB) are
responsible for the staphylococcal scalded skin syndrome of newborn and
young infants; this condition can appear just a few hours after birth. These
toxins cause the disorganization and disruption of the region between the
stratum spinosum and the stratum granulosum — two of the three cellular layers
constituting the epidermis. The physiological substrate of ETA is not known and,
consequently, its mode of action in vivo remains an unanswered question.
Determination of the structure of ETA and its comparison with other serine
proteases may reveal insights into ETA’s catalytic mechanism.
Results: The crystal structure of staphylococcal ETA has been determined by
multiple isomorphous replacement and refined at 1.7 Å resolution with a
crystallographic R factor of 0.184. The structure of ETA reveals it to be a new
and unique member of the trypsin-like serine protease family. In contrast to other
serine protease folds, ETA can be characterized by ETA-specific surface loops,
a lack of cysteine bridges, an oxyanion hole which is not preformed, an S1
specific pocket designed for a negatively charged amino acid and an ETA-
specific N-terminal helix which is shown to be crucial for substrate hydrolysis.
Conclusions: Despite very low sequence homology between ETA and other
trypsin-like serine proteases, the ETA crystal structure, together with
biochemical data and site-directed mutagenesis studies, strongly confirms the
classification of ETA in the Glu-endopeptidase family. Direct links can be made
between the protease architecture of ETA and its biological activity. 
Introduction
Epidermolytic or exfoliative toxins (ETs) are protein
toxins secreted by Staphylococcus aureus. These toxins are
responsible for the staphylococcal scalded skin syndrome
(SSSS) or impetigo contagiosa [1–3], which is primarily
observed in newborn and young infants. Babies are rarely
infected with ET-producing S. aureus at birth, but
newborns may acquire the staphylococci from healthy
nasal carriers, such as nurses. If skin infection by these
toxigenic staphylococci occurs, newborns develop the
typical SSSS, which results in splitting between the
stratum spinosum and the stratum granulosum — two of the
cellular layers constituting the human epidermis [4].
Such lesions may be at the origin of systemic infections
[5], because desquamation will expose the infant to
various bacterial infections that could lead to septicemia.
Outbreaks of SSSS are not uncommon in newborn care
units [6]. A few cases of SSSS in immunocompetent
adults [7] and HIV-1 seropositive patients have also been
reported [8]. Experimental SSSS can be obtained after
subcutaneous injection in newborn mice. They show
splitting and loss of elasticity within epidermis, which is
called the Nikolsky’s sign [2].
Two serotypes of ETs, called ETA and ETB, have been
identified and purified [9,10], and their genes have been
sequenced [11,12]. Native exfoliative toxins mature from
a longer precursor protein, which is proteolytically
cleaved of a signal peptide during the secretion process.
This signal peptide contains a sequence of positively
charged amino acid residues followed by hydrophobic
residues. The proteolytic cleavage occurs after an alanine
residue, as is the case with most of the staphylococcal
exotoxins. The ETA precursor contains 280 amino acids,
whereas the mature protein contains 242 residues.
Secreted ETA and ETB share 55% sequence identity;
they are chromosome- and plasmid-encoded, respec-
tively [12]. ETs are secreted by about 5% of S. aureus
strains isolated from patients with SSSS [13]. Two other
types of exfoliative toxins have been reported — one
from S. aureus [14] and the other from Staphylococcus
hyicus [15], but their sequences remain unknown.
Addresses:  1Institut de Génétique et de Biologie
Moléculaire et Cellulaire, CNRS/INSERM/ULP, BP
163, 67404 Illkirch Cedex, France and 2Institut de
Bactériologie de la Faculté de Médecine, 3 rue
Koeberlé, 67000 Strasbourg, France.
Present addresses:  †The Salt Lake Institute,
10010, North Torrey Pines Rd, La Jolla, CA 92037,
USA and ‡Groupe de Cristallographie Biologique,
IPBS/CNRS, 205 route de Narbonne, 31077
Toulouse Cedex, France.
*Corresponding author.
E mail:  cava@igbmc.u-strasbg.fr
Key words: epidermolytic toxin, serine hydrolase,
serine protease, Staphylococcus aureus, X-ray
diffraction
Received:  11 February 1997
Revisions requested:  11 March 1997
Revisions received:  14 April 1997
Accepted:  8 May 1997
Structure 15 June 1997, 5:813–824
http://biomednet.com/elecref/0969212600500813
© Current Biology Ltd ISSN 0969-2126
Research Article 813
Initially, ETs were thought to be proteases because of the
caseinolytic activity (cysteine protease activity) of purified
ET fractions [16]. The results presented here show that
this observation was probably due to a protein contamina-
tion during purification. Sequence analysis revealed
homology between ETs and serine proteases [17,18],
however, such as between the staphylococcal V8 protease
and a protease from Streptomyces griseus, Glu-SGP, both of
which are specific for a glutamate residue. ET sequences
include the conserved catalytic triad, Ser195(195),
His72(57) and Asp120(102), which is common to serine
proteases, esterases and lipases. (Primary sequence
numbers refer to the linear sequence of the mature
protein. Residue numbers in parentheses refer to topologi-
cal equivalences in the classical nomenclature of trypsin-
like serine proteases.). Furthermore, the functional role of
Ser195(195) was confirmed by site-directed mutagenesis.
Substitutions of Ser195(195) by glycine or cysteine
resulted in biologically inactive toxins when tested on the
newborn mouse skin model [19,20]. The physiological
target of ETs is unknown, and, despite numerous assays
with chromogenic peptide substrates, no enzymatic
activity has been evidenced [20]. No marked sequence
similarity was found between the ETs and a glutamic-
acid-specific endopeptidase from S. aureus [21]. However,
an esterolytic activity with quite poor kinetic constants
was found for both ETA and ETB with the Boc–L-
Glu–OPhenyl synthetic substrate [17].
ETs were also suspected of being superantigens [22]. They
activate Vb2+ (and to a lesser extent Vb2–) human T-
lymphocytes and, thus, cause an increase in expression of
cutaneous T-lymphocyte-associated antigen [23]. Although
it is not known whether the latter is a direct effect, or the
result of cascade events. 
Results and discussion 
Structure determination
ETA crystals belong to space group P21 with unit cell
dimensions a=49.09Å, b=66.40Å, c=81.77Å, b=93.92°,
and they diffract to a resolution limit better than 1.7 Å at a
synchrotron source. A native Patterson map gave a strong
peak (35% of the origin peak) at relative coordinates
(x=0.40, y=0, z=0.5) which was interpreted as a 
noncrystallographic translation vector between two molec-
ules in the asymmetric unit cell, corresponding to
Vm=2.46Å3/Da. Heavy-atom derivatives were prepared to
solve the phase problem, but only 2 out of 20 heavy-atom
derivatives gave significant amplitude differences with
native ETA. To overcome this difficulty, two mutated
proteins were purified and crystallized in the same space
group as wild-type ETA. Initial phases were thus
determined using two derivatives of the wild-type protein
and three derivatives of the mutants. The data-collection
and phasing statistics are given in Table 1. The structure
of ETA has been refined at 1.7 Å resolution to a
crystallographic R factor of 18.4% (see Table 2 for refine-
ment statistics). The crystallographic asymmetric unit
contains 2 molecules each of 242 residues and 417 ordered
water molecules. No metal ion binding site is present in
the ETA structure.The 2Fo–Fc map (with cross-validated
Sigmaa-weighted coefficients [24,25]) is of high quality
and shows continuous well-defined density for 97% of the
amino acids. Seven residues of each monomer have poorly
defined electron density (mainly sidechains of exposed
lysines or arginines). The model has a good stereochem-
istry—all residues, except Leu217(220) of each monomer,
are in the allowed regions of the Ramachandran diagram
(see Table 2). The final structure shows that the two
molecules in the asymmetric unit are related by a small
rotation of 6.5° around an axis (direction cosines 0.04, 0.97,
0.24) close to the b axis, followed by a translation vector of
18.47Å, –0.388Å, 41.04Å, with a root mean square (rms)
deviation between the Ca atoms of the 2 monomers of
0.267Å (the average displacement of all atoms is 0.196Å.
A trypsin-like protein fold
In Figure 1, the tertiary structure of ETA is shown as a
Ca-backbone trace. The protein contains two domains (I
and II) of similar structure, which are built around a six-
stranded antiparallel b sheet folded into a b barrel (Fig. 2).
This architecture is well-known as the serine protease
chymotrypsin-like fold, which has been illustrated by
several high resolution structures (recently reviewed in
[26,27]). Domain I is composed primarily of residues from
Arg38(27) to Asn148(129) and the C-terminal portion of
the molecule, Gly228(230)–Glu242(244), contains helix
a5 —Asn231(233)–Lys240(242). Domain II is composed
primarily of residues from Asp149(130) to Val227(229) 
and of the N-terminal portion of the molecule, Glu1(1A)–
Asp34(23), which contains helix a1, (Ser3(1C)–Gly19(7).
The catalytic tetrad, His72(57), Asp120(102), Ser195(195)
and Ser211(214) , lies at the interface between the two
domains.
The ETA structure is very similar to that of the trypsin
SGT from Streptomyces griseus [28]; this is evident from the
rms difference over 123 equivalent Ca atoms which is
1.21Å (see Fig. 3 for structural alignment and for sec-
ondary structure assignments). There are, however, large
differences between ETA and the classical trypsin-like
serine protease fold in the so-called surface loops — loop
A comprises residues 50(34)–56(41), loop B residues
74(59)–84(64), loop C residues 113(91)–119(101), loop D
residues 165(145)–167(152), loop 1 residues 187(184)–
189(189), loop 2 residues 213(216)–223(225) and loop 3
residues 179(164)–184(181). Among a number of chymo-
trypsin-like serine proteases, loops A,B,C and D are
known to be involved in determining subsite preferences,
whereas loops 1,2 and 3 influence the specificity of the S1
site [26]. As in mammalian proteases, the C-terminal helix
of ETA packs against the hairpin containing the catalytic
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Asp120(102) and helps to fix its geometry. In contrast to
other serine protease folds, however, ETA is characterized
by three unique structural features: firstly, an unusual and
inactive conformation of the so-called oxyanion hole;
secondly, an additional amphipathic N-terminal helix a1
(Ser3(1C)–Gly19(7)), which interacts with loops 1 and 2;
and, thirdly, an absence of cysteine bridges. In all members
of the chymotrypsin family of serine proteases, with the
exception of the Sindbis virus core protein, three conserved
disulfide bonds (C42–C58, C168–C182 and C191–C220,
chymotrypsin sequence numbering) connect the short
loops. They are probably important for structural stability.
None of these bridges are present in ETA.
The presence of two molecules in the asymmetric unit
has no biological relevance and is only due to the special
packing arrangement. The interfacial area between the
two molecules of the asymmetric unit is low — the buried
surface area is 426 Å2 per monomer, compared to the
overall accessible surface area per monomer of 10 555 Å2.
The interactions are mainly water mediated and involve
loops A and B of one monomer interacting with loop 2
and the b hairpin (b6–b7) of the other monomer. 
The oxyanion hole of ETA is not preformed
Extensive studies on serine proteases have shown that
the cleavage of a peptide bond by these enzymes
proceeds through a two-step reaction. Each step proceeds
through a negatively charged tetrahedral transition state
intermediate. In trypsin-like serine proteases, the
negative charge developed during the breaking of the
scissile bond is usually stabilized in a pocket called the
oxyanion hole, by the mainchain atoms of residues
located in the vicinity of the catalytic serine. The NH
groups of both Gly(193) and Ser(195) play this role in
SGT and several other serine proteases.
In the ETA structure, the corresponding peptide,
Pro192(192)–Gly193(193), has a unique conformation that
has never been observed in serine proteases so far. The
CO group of Pro192(192) and the NH group of
Gly193(193) point in the opposite directions to those
groups in the oxyanion hole of other serine proteases
(Fig. 4). In this conformation, the mainchain CO of
Pro192(192) makes a hydrogen bond with Og of the
catalytic Ser195(195) and the mainchain NH group of
Gly193(193) hydrogen bonds with Od1 of Asp164(144)
from loop D. This conformation of the oxyanion hole also
implies that His72(57) is protonated, the Nε2 atom
making a hydrogen bond with Og of the catalytic
Ser195(195). In the classical serine protease catalytic
scheme, the CO of Pro192(192) could be directed toward
the negative charge developed in the tetrahedral transi-
tion state, and the NH of Gly193(193) would not be able
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Table 1
Data collection and phasing statistics.
Data set
Native 1 Native 2 Mersa KAuCl4 EtHgCl DiHgCl PCMBS
Protein* (ETA) wild type wild type wild type wild type S195C S195C S147C
X-ray source Lure Lab Lab Lab Lab Lab Lab
Wavelength (Å) 0.9 1.5418 1.5418 1.5418 1.5418 1.5418 1.5418
Resolution (Å) 10–1.7 27–3.1 27–3.1 27–3.35 27–2.7 27–2.7 30–3
Number of observations 226 508 46 207 44947 37 400 34 477 39 326 30 277
Number of unique reflections 57 158 9 141 8 542 7508 13 247 13 866 10 816
Completeness (%) 99 95 88 98 91 95 98
1.7 Å–1.8 Å (F/σ > 3) 85
Rsym †(%) 
all range 4.8 5.2 5.5 5.5 7.7 7.1 3.4
1.7 Å–1.73 Å
(9807 obs/ 2810 reflections) 17.7
Heavy atom concentration (mM) 4 3 2 2 1
Soaking time (h) 12 24 4 4 1
Number of sites per molecule 4 4 1 2 1
Riso‡ (%) 15.4 16.1 22.9 20.7 8.4
Phasing power§ (centric–acentric) 0.76–1.1 1.2–1.4 0.81–0.96 1.20–1.35 1.1–1.05
Rcullis# (centric–acentric) 0.9–0.92 0.86–0.83 0.90–0.92 0.84–0.83 0.91–0.9
*Proteins used for data collection: wild type; mutant (S195C), where
Ser195 has been substituted by Cys; mutant (S147C), where Ser147
has been substituted by Cys. †Rsym= ShSi |< Ih > –Ih,i | / ShSi Ih,i, where
Ih,i is the intensity of a measured reflection h and < Ih > is the average
intensity for this unique reflection. ‡Riso = Sh |Fder–Fnat | | / Sh Fnat, where
Fnat and Fder are the native and derivative structure factor amplitudes.
§Phasing power = (root mean square heavy atom structure factor)/
(phase integrated lack of closure) (statistics of SHARP). #Rcullis = (phase
integrated lack of closure)/(root mean square isomorphous difference)
(statistics of SHARP). Heavy atoms abbreviations: Mersa (mersalate
sodium mersalyl), KAuCl4 (potassium tetrachloro aurate), EtHgCl
(chloro ethyl mercury), DiHgCl (1-2 toluidine,-4,6 dimercuriacetate) and
PCMBS (p-chloromercuribenzene sulfonate).
to stabilize this negative charge. The electron-density
map of ETA is of very good quality and does not allow
alternative interpretations of this loop (Fig. 5). The tri-
peptide Pro192(192)–Gly193(193)–Asn194(194) adopts a
310-helical conformation. The classical stabilization of the
developed charge would require a conformational change of
this loop, which would only need a rotation of the psi angle
of Pro192(192) from one conformationally favorable domain
(helical, ψ=–40°) to the other one (strand, ψ=140°). This
conformational switch should not be energetically expen-
sive—on the basis of free energy simulations of a small
polypeptide where a similar conformational change was
analyzed [29], the flipping of this bond would cost less than
3Kcal/mol. Moreover, the residues implicated in this
conformational change, namely Asp164(144) of the D loop
and Pro192(192)–Gly193(193), are located at the surface of
the molecule and no steric constrains should therefore
interfere during this local structural switch. One may
therefore postulate that a productive oxyanion hole can be
formed upon substrate binding.
This unexpected feature of the ETA active site may
corroborate a previously unexplained experimental behav-
iour of our ETA crystals—even at relatively high pressure
(20 bars), ETA crystals do not bind Xenon. It has been
shown that Xenon binds to several serine proteases in the
catalytic site [30], at a site approximately midway between
the catalytic serine Ser(195) and the S1 (primary
specificity) pocket with very little perturbation of the
protein. It was expected that Xenon binding would be a
general feature of serine proteases. ETA is the first
example of a serine protease that contains an oxyanion hole
which is not preformed. Lipases, which possess the same
catalytic triad as serine proteases but with a large variation
in the chemistry and structure of this triad, also have an
oxyanion hole that is not preformed. However, the
productive oxyanion hole of lipase is generated by an
activation process, induced by a displacement of the
protein region that covers the catalytic site which is initially
hidden from the protein surface and therefore inaccessible
[31–33]. Therefore, the conformational switch necessary
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Figure 1
A stereo representation of the ETA Ca
backbone. This figure was made with the
program SETOR [64]. Numbering is only
shown according to the mature sequence of
ETA.
Table 2
Refinement statistics.
Refinement program X-PLOR
Resolution (Å) 8–1.7
Number of reflections (F > 3σ) 53 177 
Number of non-hydrogen proteins atoms (mola, molb) 1905–1905
Number of ordered water molecules 417
Rmodel* (%) 18.4
Rfree†(%) 23.6
Overall G factor‡ (mola, molb) 0.23–0.25
Average B factors (Å2)
all non-hydrogen atoms (mola, molb) 19.6–17.6
mainchain (mola, molb) 17.1–14.9
sidechain (mola, molb) 22.1–20.3
water molecules 39.1
Root mean square deviations from ideal geometry§
bonds (Å) (mola, molb) 0.005–0.006
angles (°) (mola, molb) 1.241–1.252
torsion(°) (mola, molb) 27.6–27.4
Ramachandran plot quality
residues in core regions (%) (mola, molb) 89.3–88.8
residues in allowed regions (%) (mola, molb) 9.8–10.7
residues in generous or
disallowed regions (%) (mola, molb) 0.5–0.5
Coordinates errors from cross-validated
Luzzati plots (Å) 0.21
(0.18, 
working set)
*Rmodel = Sh|Fobs–Fcalc |/ Sh Fobs, where Fcalc and Fobs are the calculated
and observed structure factor amplitudes, respectively. †A small fraction
(7%) of reflections with no cut-off between 8 Å–1.7 Å (4065 out of
57140 unique reflections) was excluded from the refinement and used
for monitoring the course of the refinement. ‡Overall ‘normality’ as
calculated by PROCHECK [60]. §Root mean square deviations were
calculated using Engh and Huber parameters. mola and molb represent
the two non-crystallographic molecules in the asymmetric unit.
for building the oxyanion hole of ETA will be different as
the active site is accessible at the protein surface.
An S1 subsite specific for a glutamic acid residue
Looking at ETA from the outside of the molecule toward
the catalytic tetrad, and by homology with the other serine
proteases, the primary specificity pocket S1 (using the
nomenclature introduced by Schechter and Berger [34]) is
located at the right-hand side of the molecule (Fig. 2).
This pocket is delimited by three polypeptide portions of
domain II—loop 1, strands b14 and b15, which flank loop
2, and the N-terminal helix a1. The residues mapping to
this region and which should be important for the subsite
specificity of ETA are His210(213), Lys213(216), Tyr186
(183) and Thr190(190) (Figs 2, 4).
As predicted by Barbosa et al. [35], the ETA S1 pocket may
preferentially bind negatively charged substrates that can
be stabilized by His210(213). In the back of the pocket,
Tyr186(183) is responsible for orienting His210(213). In our
crystal structure, a network of water molecules occupies the
active site and the entrance of the S1 pocket of ETA, and
they link His210(213) to the catalytic triad.
In vitro enzymatic experiments (see below) have shown
that ETs hydrolyse a synthetic substrate Boc–L-
Glu–OPhenyl, but do not cleave Boc–L-Asp–OPhenyl.
Superposition of the ETA structure on that of the
glutamic acid serine protease Glu-SGP in complex with a
tetrapeptide ligand Boc–Ala–Ala–Pro–Glu–OH [36,37],
shows that His213(210) and Ser190(190) of Glu-SGP,
which recognize the glutamate moiety of the substrate
occupy the same spatial positions as His210(213) and
Thr190(190) of ETA (Fig. 6). Therefore, these two
residues should play a similar role in substrate binding.
The superposition also shows that Lys213(216) of ETA
would interact with the sidechain of the glutamate moiety
in the S1 pocket. Sequence alignments and structural
comparisons of several serine proteases reveal that
Lys213(216) is specific for ETs, whereas the other serine
proteases have small residues (glycine or serine) at this
position (see Fig. 3 for a subset of sequences). In the ETA
crystal structure, Lys213(216) also stabilizes the conforma-
tion of the S1 pocket by hydrogen-bond interactions with
the OH group of Tyr18(8) and the backbone CO atom of
Thr190(190). Asn224(226) at the bottom of the S1 pocket
could also be a potential candidate for substrate stabiliza-
tion. Although as this residue is replaced by phenylalanine
in ETB, it may only have a structural role. 
The ETA-specific amphipathic N-terminal helix
Another characteristic of ETA not seen in other members
of the serine protease family is an N-terminal extension of
approximately 30 residues. This region adopts an a-helical
conformation and packs against domain II. This helix a1
closes one entrance of the S1 subsite and plays a crucial role
in its geometry, Tyr18(8) and Trp14(2) being buried in the
S1 pocket. Helix a1 is also responsible for the open confor-
mation of loop 2. In all other trypsin-like serine proteases,
except for the core protein of Sindbis virus, loop 2 folds
back towards the core of domain II, forming a conformation
which is partly stabilized by the presence of a disulfide
bridge between loop 1 and loop 2. Loop 2 of ETA, that
does not contain a cysteine bridge, has an extended confor-
mation which is constrained by several hydrogen-bond
interactions with residues belonging to helix a1.
The crucial role of the N-terminal helix of dictating the
conformation of the S1 specific pocket and therefore the
substrate specificity of ETA has been confirmed by in
vitro experiments using a synthetic substrate (Boc–L-
Glu–OPh), which is hydrolyzed by ETA. Deletion experi-
ments in the N-terminal extremity of ETA result in an
inactive protein (see later discussions).
Enzymatic properties of wild-type and mutant ETs
In vitro enzymatic properties
Unlike other Glu-endopeptidases, such as the V8 protease
that has the highest sequence homology with ETA, ETs
do not show any in vitro proteolytic activity against insulin,
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Figure 2
Schematic drawing of the structure of ETA. The two domains, built
around a six-stranded antiparallel b sheet characteristic of the trypsin-
like serine protease fold, are shown in green for domain I and in red for
domain II. The location of the catalytic tetrad, His72(57), Asp120(102),
Ser195(195) and Ser211(214), is shown together with the amino acid
residues which map the S1 specific pocket. The canonical surface
loops [26] (loops A, B, C, D, 1, 2 and 3) are shown in blue. Numbering
is only shown according to the mature sequence of ETA.
casein or bovine serum albumin —proteins which are
commonly used as protease substrates in vitro. This means
either that the natural substrate has multisubsite
specificity, or that ETA activity is modulated in vivo by
another molecule.
Despite observations that ETs did not have any proteolytic
activity in vitro, Takiuchi et al. [16] reported a detectable
caseinolytic activity (cysteine protease activity) of ETs, but
only when incubated in the presence of crude extract of
epidermis of newborn mice. They postulated that the crude
extract of the epidermis contains an activating factor of
ETA. Our results show that this caseinolytic activity is due
to a contamination of ETs by other proteins. We observed
that E64, a cysteine protease specific inhibitor, was able to
completely inhibit the observed caseinolytic activity
(Fig. 7), without modifying the biological activity of ETA
on the crude extract of mouse epidermis or its esterolytic
activity (data not shown). A new purification procedure of
ETA has therefore been developed, which avoids
ammonium sulphate precipitation and gives non-contami-
nated ETA. ETs do not hydrolyze in vitro substrates, 
such as Boc–Ala–Ala–Pro–Glu–p-nitroanilide(pNA) and
anthranilyl–Ala–Phe–Ala–Phe–Glu–Val–Phe–nitro–Tyr–As
p, some of which are also cleaved by the V8 protease [38].
Although ETA and ETB purified with our current
protocol (see Materials and methods) display an esterolytic
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Figure 3
Sequence alignment for ETA, ETB, V8
protease, S. griseus trypsin (SGT) [28],
S. griseus glutamic acid-specific protease
(Glu-SGP) [36], S. griseus protease A (SGA)
[65], S. Griseus protease B (SGB) [66] and
Lysobacter enzymogenes α-lytic protease
(ALP) [67]. Amino acid sequence alignment
for ETA, SGT, Glu-SGP, SGA, SGB and ALP
is based on structure superpositions done
with the program WHATIF [61]. The rms
deviations after superposition on the ETA
structure using atoms differing by less than
2.5 Å are 1.21 Å for SGT (121 atoms used),
1.07 Å for Glu-SGP (73 atoms used), 1.04 Å
for SGA (64 atoms used), 1.22 Å for SGB (74
atoms used) and 1.28 Å for ALP (75 atoms
used). Secondary structure, determined with
program PROMOTIF [68], is also displayed
for ETA. Elements of secondary structure are
indicated by: a for a helix, b for strand of b
sheet, ξ for 310 helix. ETA numbering is shown
above the sequence of ETA, whereas
canonical trypsin-like serine protease
numbering is shown above the sequence of
SGT. The residues of the catalytic tetrad are
highlighted in orange and the residues of the
S1 specific pocket are highlighted in green.
The positions of the so-called surface loops
(A, B, C, D, 1, 2 and 3) [26], corresponding to
those found in the SGT structure are
highlighted in yellow. Other residues of similar
chemical nature in the aligned sequences
(boxed) are either involved in the active site or
stabilize the interface between the two
domains of the molecule. Asn194(194) and
Ser197(197), specific for ETA, ETB and V8
protease, are hydrogen bonded to each other
in the ETA structure and stabilize the
conformation of the active site. This figure was
made with the program ALSCRIPT [69].
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activity when tested with the synthetic substrate Boc–L-
Glu–OPhenyl, neither hydrolyze Boc–L-Asp–OPhenyl nor
Boc–L-Glu–pNA. These data favor the specificity of the
S1 subsite for a glutamic acid; Boc–L-Glu–pNA is not
hydrolyzed by ETA due to steric hindrance of the NO2
group by Thr55(40) and Phe76(61) in the S1′ subsite.
The low Km values for ETA (7.5 mM) and ETB (2.2 mM)
observed for Boc–Glu–OPhenyl hydrolysis are in the
range of those previously published [17], whereas the
specific activity and Kcat/Km values are much higher
(Table 3). Amino acid substitutions in ETA of the three
residues of the catalytic triad —His72(57), Asp120(102),
Ser195(195)—result in a protein with no detectable
biological activity in vitro. Moreover, deletion of the first
ten residues at the N-terminal side (Table 3, ETA
DGlu1(1A)–His10(1J)) reduced dramatically the kinetic
values of the enzyme and deletion of the first twenty
residues—the whole helix a1, (Table 3, ETA Glu1(1A)–
Val20(9)) produced an enzyme with an undetectable level
of activity. These observations further support the role of
the N-terminal a-helix in the stabilization of the S1
pocket as observed in the crystal structure. The two
deletions in the C-terminal side from Ile236(238) to
Glu239(241) also resulted in inactive proteins. This
observation can easily be explained by the fact that the C-
terminal helix forms a hydrophobic interface with strands
b8–b9, containing Asp120(102), and is involved in the
stabilization of the active site. Consequently, wild-type
ETs cannot be considered as precursors needing further
maturation in order to be activated. 
In vivo biological activity
Wild-type and mutant ETA described above have been
subcutaneously injected into newborn mice. After
incubation, the animals were examined in order to observe
whether the injected ETA was able to induce the signs of
Nikolsky syndrome (Table 3). Unlike wild-type ETs,
injection of ETA mutants did not give rise to 
the characteristic Nikolsky’s sign, except for ETA
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Figure 4
Detailed stereo view of the oxyanion hole and
the S1 specific pocket of ETA. The location of
the catalytic tetrad, His72(57), Asp120(102),
Ser195(195) and Ser211(214), and the
oxyanion hole, Thr190(190), His 210(213),
Lys213(216), Asn 224(226), Tyr186(183),
Tyr18(8) and Trp14(2), are shown. Sequence
numbering is only shown according to mature
ETA.
Figure 5
The active site of ETA. Stereo view of the final
(2Fo–Fc) cross-validated Sigmaa-weighted
map (resolution limits 8 Å–1.7 Å, all data are
used, contour level 1σ). Sequence numbering
is only shown according to mature ETA.
DGlu1(1A)–Val10(1J) of which a 100 fold higher dose than
wild-type ETA was necessary to obtain experimental
SSSS. Therefore, there is a very good correlation between
in vitro enzymatic activity with Boc–L-Glu–OPhenyl
substrates and biological capacity of mutant ETA to
induce the Nikolsky’s sign in newborn mice. These
observations are in accordance with the possible
hydrolytic activity of ETs in the clinical SSSS.
Biological functions of ETs
The X-ray structure of ETA, together with site-directed
mutagenesis experiments, confirms the biological activity
of ETA as a serine hydrolase with S1 subsite specificity for
a glutamic acid. Mutations of the essential amino acids of
the catalytic triad induced the loss of the enzymatic
potential, as well as the loss of the functional ability of the
toxin to generate the typical splitting of the two epidermal
cell layers of newborn mice. ETA may hydrolyze proteins
involved in the cell-to-cell attachment in the epidermis.
Such proteins would be specific for the interface between
two typical cell layers, as shown by cleaving activity
experiments in epidermal cell cultures [39]. These
specific proteins are expected to disappear almost
completely in adults, because it is known that newborns
and children are more susceptible to SSSS. Interactions
between ETA and these target proteins might result in
structural modifications leading to an active form of ETA,
as is the case with most serine proteases (upon interaction
with coagulation factors or plasmin) involved in precise
biological processes. N-terminal or C-terminal processing
of the ETA would not occur since ETA activity is
sensitive to such deletions.
The catalytic triad (Asp, His and Ser) is common to
proteases, esterases and lipases. Lipases differ from
esterases and proteases in being inactive in the absence of
a lipid–water interface; this is certainly not the case for
ETA. Distinctions between the esterase or protease
activity of ETA is not so simple, as it is well known that
serine proteases like chymotrypsin also act as esterases.
As the mode of action of ETs on the epidermis is unknown,
ETs have also been postulated to be superantigens [40].
The clinical syndrome associated with ET-producing S.
aureus strains does not evoke a pathology analogous to that
provoked by superantigens. Superantigens stimulate
cytokine production from lymphocytes, generating fever,
hypotension, skin rashes and various disorders in patients.
SSSS in newborns may develop rapidly after birth and is
only signaled by superficial desquamation without general
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Figure 7
Caseinolytic activities of the previously purified ETA were obtained in the
absence of the cysteine-protease inhibitor E64 (solid circle symbol) and
disappeared in the presence of E64 (open circle symbol). This activity
was monitored by the release of caseine derivative fluorescence-labelled
peptide. The highly purified ETA (new protocol presented in this paper)
in the absence (solid triangle symbol) or in the presence (solid square
symbol) of E64 did not harbour any caseinolytic activity. 
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Figure 6
Comparison of the oxyanion hole and the S1
specific pocket of Glu-SGP and ETA. ETA
structure together with ETA sequence
numbering are shown in gold, whereas Glu-
SGP structure together with Glu-SGP
sequence numbering are displayed in blue.
The Boc–Ala–Ala–Pro–Glu–OH synthetic
substrate of Glu-SGP is shown in green. The
conformational switch, around Pro192(192)
of ETA, necessary for creating a productive
oxyanion hole is here clearly illustrated.
symptoms such as fever, hypotension and T cell prolifera-
tion [2]. Experimental cleavage within keratinocyte cell
culture was obtained with ETA [39], which suggests no
such role for an intermediate cell-like Langerhans cells that
represent specialized cells located within the dermis and
which are able to promote an immune response. Histologi-
cal examination of skin with SSSS never mentioned recruit-
ment of immune cells. Superantigen activity is well
understood for proteins that interact simultaneously with
major histocompatibility complex (MHC) class II molecules
on antigen-presenting cells and with the variable parts of
the lymphocyte T cell receptor (TCR). Therefore, clinical
and experimental observations of SSSS do not account for a
superantigen activity of ETs. To date, no hydrolytic activity
has been reported from any recognized superantigen. No
superantigen activity for ETA was observed by Fleischer et
al. [41] who carried conventional experiments with purified
ETA and also tested a recombinant toxin. Recently, Inoue
et al. [42] published results on Vβ specificity and expression
of a cutaneous lymphocyte-associated (CLA) antigen [23];
they used ETA from a commercial source. No CLA
response was observed when testing our purified fractions
of ETA and ETB, which remained functional on the animal
experimental model (T Zollner, personal communication).
The last observation suggests a contamination of purified
fractions by known or unknown superantigens, some of
which may not have been detectable to date [43]. Such
contamination might be of great consequence because
superantigens are known to be biologically active at very
low concentrations [40].
Biological implications
Staphylococcal epidermolytic toxins A and B (ETA and
ETB) are the two protein toxins (ETs) secreted by S.
aureus that are responsible for the staphylococcal scalded
skin syndrome (SSSS) or impetigo contagiosa [2], which is
observed in newborns and young infants. The secreted
forms of ETA (242 amino acid residues) and ETB (245
amino acid residues) have 55% sequence identity and are
chromosome- and plasmid-encoded, respectively. They
cause disorganization and disruption of the stratum
spinosum and the stratum granulosum —two of the three
cellular layers constituting the epidermis. This results in
a bullous syndrome with significant desquamation,
which exposes infants to various bacterial infections that
may lead to septicemia. The SSSS can be reproduced in
vivo by cutaneous injection of ETA into newborn mice
and in vitro by addition of ETA to keratinocyte cell
cultures. The physiological substrate of ETs is unknown,
however, and, consequently, the mode of action of ETs
in vivo remains an unanswered question. The hydrolytic
activity of exfoliative toxins may be exerted on intercellu-
lar junctions, which are made up of protein molecules,
therefore, the hypothesis of a phospholipase function of
exfoliative toxins is not convincing. A superantigen
activity for ETs has also been proposed, despite the
absence of any clinical observations associated with
SSSS resembling a superantigen-induced pathology.
ETA does not cleave in vitro any of the proteins that are
hydrolyzed by other Glu-endopeptidases. ETA was found
to have esterolytic activity against a synthetic substrate
Boc–L-Glu–OPhenyl only. Site-directed mutagenesis has
shown that ETA mutants defective for this esterolytic
activity in vitro were also unable to induce experimental
SSSS when cutaneously injected into newborn mice.
The crystal structure of ETA has been determined by
multiple isomorphous replacement and refined to a high
resolution (1.7Å). Sequence alignments reveal weak
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Table 3
Esterolytic properties of ETA.
VM Specific activity Km Kcat/Km Kcat Minimal dose##
(mM min–1) (mM min–1mg–1) (mM) (mM–1s–1) (s–1) (mg)
*ETA 256.5 ± 40 47.1 ± 8.0 7.5 ± 0.5 2.81 ± 0.07 21.2 ± 3.0 0.5
†ETB 121 ± 9 28.3 ± 1.9 2.2 ± 0.2 5.84 ± 0.11 12.8 ± 0.9 0.5
‡ETA S195C < 1.0 < 0.5 > 80 > 0.01 > 0.7 > 180
§ETA H72Y < 1.0 < 0.5 > 80 > 0.01 > 0.7 > 180
#ETA D120T < 1.0 < 0.5 > 80 > 0.01 > 0.7 > 180
**ETA ∆ E1-H10 16 ± 3 2.1 ± 0.4 72 ± 12 0.025 ± 0.005 1.8 ± 0.3 40–50
††ETA ∆ E1-V20 < 1.0 < 0.5 > 80 > 0.01 > 0.7 > 180
‡‡ETA ∆ I236-E242 < 1.0 < 0.5 > 80 > 0.01 > 0.7 > 180
§§ETA ∆ I236-E239 < 1.0 < 0.5 > 80 > 0.01 > 0.7 > 180
In vitro esterolytic properties of ETA for the Boc–L-Glu–OPhenyl
synthetic substrate hydrolysis were measured by the release of phenol
(monitored at 270nm). These values were obtained in 0.2M KH2PO4 pH
7.8–1% (v/v) dioxane containing the Boc–L-Glu–OPhenyl compound
(0.05–10mM) at a concentration of 0.17mM epidermolysins. *Wild-type
ETA, †wild type ETB, ‡ETA Ser195(195)Cys mutant, §ETA His72(57)Tyr
mutant, #ETA Asp120(102)Thr mutant, **,††ETA truncated at the N-
terminal side, ‡‡,§§ETA deleted at the C-terminal side. ##Minimal dose
required for observing, in vivo, a Nikolsky sign in newborn mice;
observations were made 6h after injection (180mg represents the limit
of protein concentration in 50ml of physiological solution). 
homologies between the staphylococcal V8 protease and
ETs, but show that ETs contain the catalytic triad (Ser,
Asp and His) common to proteases, esterases and lipases.
Mutations of any of the amino acids of the catalytic triad
lead to an inactive protein. Despite a very weak sequence
homology between ETA and the trypsin-like proteases,
ETA displays the well-known fold characteristic of such
proteases—containing two domains of similar structure,
which are built around a six-stranded antiparallel b sheet
folded into a b barrel. The interface of the two domains
contains the conserved catalytic tetrad—His72(57),
Asp120(102), Ser195(195) and Ser211(214). The S1
subsite is specific for binding a negatively charged
substrate, particularly, a glutamic acid. The S1 subsite
has characteristics found in other Glu-endopeptidases,
nevertheless, the ETA structure reveals new and
unexpected features. Firstly, there are large differences in
the conformation of ETA’s surface loops that decorate
the two-barrel structure, especially loop 2 which has an
uncommon extended conformation. Secondly, the
putative oxyanion hole, which is involved in the stabiliza-
tion of the tetrahedral transition states of the proteolytic
reaction, has an unusual and inactive conformation
requiring a molecular switch with low energy cost for
activity. Thirdly, disulfide bridges, which are conserved in
chymotrypsin-like serine protease and are suspected to be
important for either structural stability or active-site
stabilization are not present in ETA. And finally, ETA
possesses an additional N-terminal extension of 20
residues which folds into an amphipathic helix. The
crystal structure shows that this helix is important for
ETA biological activity, as it stabilizes the S1 specific
subsite; this is confirmed by the biological inactivity of
mutants truncated at the N-terminal end. Together with
site-directed mutagenesis, the structure of ETA gives a
strong argument in favour of the classification of ETA in
the serine protease subfamily of proteins that cleave
preferentially after a negatively charged residue, namely a
glutamic acid. In order to assess such a specific activity, it
would be convenient to use labeled biologically active
mutants and to check the binding of ETA at the surface
of keratinocyte cells. Covalent binding or two-dimensional
electrophoresis would be instrumental in characterizing
the target molecules of staphylococcal epidermolysins. 
Materials and methods
Purification of exfoliative toxin A 
S. aureus strain IBS-SA417 (Institut de Bactériologie de Strasbourg S.
aureus) or recombinant strain 8325-4, which contains mutated genes,
were grown at 37°C under an atmosphere containing 10% CO2
(150 × rpm) in 2l Erlenmeyer flasks filled with 1l of 2 × TY. Culture was
filtered (Ø =0.45mm) on Pellicon cassette system (Millipore) and the
supernatant was further concentrated (cutoff 10 000 Da) to 1l before
being dialyzed against H2O at +4°C. The solution (pH =5.0) was
applied to a SP Fast Flow column (Pharmacia, Uppsala, Sweden).
Proteins that were eluted with a discontinuous gradient of 90 mM
NaCH3COO pH 5.0 (buffer 1; NaCl gradient 600 mM) were then
dialyzed against buffer 1 and chromatographed on a MonoS FPLC
(Pharmacia) using a NaCl gradient (0–300 mM) in buffer 1. ETs
fractions (180 mM) were pooled and adjusted to 2 M (NH4)2SO4 before
being applied to an alkyl-Superose FPLC (Pharmacia) and eluted in a
(NH4)2SO4 gradient (2–0 M) in 50 mM KH2PO4 pH 7.0. ETs eluted at
about 1.6 M (NH4)2SO4 were dialyzed against H2O before being further
purified on a MonoS using a LiCl gradient (0–1 M) in 30 mM MES,
1mM DTT pH 5.8. Proteins that were eluted around 100 mM LiCl were
concentrated onto Macrosep Filtron 10 000 then onto Minicon 10 000
(Amicon, Epernon, France), and desalted on PD10 column (Pharmacia)
with 50 mM Na2HPO4/NaH2PO4, pH7.0, without DTT. The protein was
concentrated at 20 mgml–1 and stored at 0°C. The purified ETs
conserved their ability to induce the Nikolsky’s sign when injected
subcutaneously into newborn mice.
Enzymatic assays
Caseinolytic assays were performed in 10 mM Tris-HCl, 150 mM NaCl,
1mM DTT, pH 8.0 at 37°C. Fluorescein-labeled casein (Sigma) and ETs
were used at 480 mg/ml and 100 mg/ml, respectively. After 30 min, 2 h,
4h or 8h, macromolecules contained in 400 ml aliquots were pelleted
by centrifugation with 1% (w/v) trichloracetic acid for 10 min at 0°C. The
supernatant (350 ml) was neutralized by adding 150 ml of 0.2 M Tris-HCl
pH8.0 before the measurement of absorbance at 490 nm. Proteolysis
assays in 0.2 M KH2PO4 pH7.8 were done on lapsed lots of insulin
(Lilly, France) and human growth hormone (Kabivitrum, Noisy le Grand,
France) for 4 h at 37°C, then analyzed on a PHAST system (Pharma-
cia) using 20% polyacrylamide gels. For esterolytic activities, Boc–L-
Glu–OPhenyl (Sigma) was prepared in dry 1-4 dioxane (Aldrich) as a
500mM solution and assayed on a DU-40 spectrophotometer
(Beckman). Esterolytic activity or NaOH hydrolysis of the substrate was
determined by using a molar absorption coefficient of 1.5 mM-1 cm-1 at
270nm [44]. At 30°C, the Km, vi, Vmax, kcat values were measured by
using 0.5 to 5mM of substrate at 37°C in 500 ml assays containing 1%
1-4 dioxane (v/v) and 2 mg of each ETs, according to Michaelis–Menten
kinetics. Among several buffers, such as 0.2 M KH2PO4/Tris pH 7.8,
0.05 M Bicine pH 7.8, 0.05 M Hepes pH 7.3, KH2PO4 0.2M pH7.8
with and without 2 mM CaCl2, only the hepes buffer, with or without
CaCl2, gave the most accurate kinetics. Other substrates, Boc–Ala–
Ala–Pro–Glu–pNA (where pNA is p-nitroanilide), Boc–L-Glu–pNA,
Boc–L-Asp–OPhenyl, Boc–L-Glu–OPhenyl and anthranilyl–Ala–Phe–
Ala–Phe–Glu–Val–Phe–nitro–Tyr–Asp (Sigma), were tested in the
same conditions as above.
Site-directed mutagenesis 
Site-directed mutagenesis of the ETA gene inserted in M13mp19 [45]
was carried out as previously described [20]. Mutations were
sequenced [46] before ETA mutated genes were inserted into the Gram
(–)/Gram (+) pCU1 shuttle vector [47] by a HindIII-HindIII restriction.
Vectors containing mutated genes were used for electrotransformation
[20] of S. aureus RN4220 (r– m+ agr–), and then of S. aureus 8325-4
(r+ m+ agr+), which efficiently expresses the ETA gene.
Crystallization
Initial crystallization conditions were found by screening different
precipitation agents. The best crystals were grown at 4°C by vapor
diffusion against a reservoir containing 18% PEG 4000, 50 mM
sodium phosphate buffer pH 7.0. For the final setup, 5 ml of reservoir
solution were mixed with 4 ml of protein solution (initial concentration of
17.7 mg/l) and 1 ml of DMSO. Crystals grow after few days as thin
plates. Crystal quality was improved by a new purification scheme
described above. Initial diffraction analysis showed twinning problems
for some crystals. Subsequently, diffraction data were carefully
examined in order to use only single crystals for complete data collec-
tion. Wild type ETA, mutants S195C and S147C were crystallized in
the same conditions and belong to the same space group.
Data collection
X-ray diffraction data were collected at 4°C on 18 cm Mar-Research
image plates and with a Siemens 2D area detector. Laboratory data
were collected on a Rigaku rotating anode generator with graphite
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monochromator. Synchrotron data for the native were collected at the
wiggler station W32 of the Laboratoire pour l’Utilisation du
Rayonnement Electromagnetique (LURE), Orsay, France. A native data
set between 27 Å and 1.7 Å resolution was obtained by merging a high
resolution data set (nat1) collected at LURE and a low resolution data
set (nat2) data set collected in the laboratory. For the synchrotron data
set (nat1), 243 frames of 0.8° oscillation were collected between 15 Å
and 1.7 Å resolution from one crystal. The nat2 data set was collected
between 27 Å–3.1 Å resolution; scaling of the two sets was done using
data in the resolution range 6 Å–3.5 Å (Rmerge =3.5% between the two
data sets, calculated on F). After scaling, the final native data were made
of reflections from nat1 in the resolution range 6 Å–1.7 Å and of reflec-
tions from nat2 in the resolution range 27 Å–6Å. The final native data
set was 99% complete between 27 Å–1.7 Å (57 263 reflections). Data
sets were processed with the programs DENZO and SCALEPACK [48]
(for image plates data), XDS [49] (for area detector data). 
Phasing 
Heavy atom binding sites were determined by difference Patterson and
Fourier difference maps. Four derivatives (Mersalyl, KAuCl4, EtHgCl,
DiHgCl) have a common binding site on each molecule which
corresponds to the serine protease active site — (Ser195(195),
Asp120(102), His72(57). Refinement of the heavy-atom parameters
was performed by the maximum likelihood approach as coded in the
programs MLPHARE and SHARP [50,51]. The calculated phases gave
an overall figure of merit of 0.622 for data between 27 Å–3.3 Å resolu-
tion (SHARP statistics). The 3.3 Å map was improved by solvent
flattening, solvent flipping, histogram matching and non-crystallo-
graphic symmetry averaging with the programs DM [52] and
SOLOMON [53]. All crystallographic calculations were carried out with
programs in the CCP4 package [50].
Model building and crystallographic refinement
The modified 3.3Å resolution MIR map allowed chain tracing for most
parts of the polypeptide chain, and a polyalanine model of the ETA
molecule was built using the graphics program O [54]. Phases obtained
by combining MIR phases with those derived from the polyalanine model
using the program SIGMAA [24] were then modified at 3.3Å resolution,
and extended to 2.7Å by solvent flattening, solvent flipping, histogram
matching and non-crystallographic symmetry averaging. This phase
modification process combined with model building was repeated
several times. The amino acid sequence could be fitted unambiguously
for most of the chain to give an initial model which included all 242
residues per monomer. The model was refined with the program X-PLOR
[55], using the Engh and Huber stereochemical parameters [56]. Initially,
only 3Å resolution data were included for rigid body refinement followed
by torsion-angle refinement. The crystallographic R factor for the starting
model was 41.8%. A random sample containing 7% of the data was
excluded from the refinement and used for monitoring the course of the
refinement [57]. Torsion-angle refinement at 3Å was followed by rounds
of model building in cross-validated Sigmaa-weighted maps with coeffi-
cients (2Fo–Fc) and (3Fo–2Fc) [25,58] and by torsion angle refinement, in
which the maximum resolution of the data was gradually increased.
Beyond 2.5Å, the refinement of the atomic parameters was alternated
with the refinement of the atomic temperature factors. When the R factor
had dropped to 23%, water molecules were added at positions with
density higher than 5σ in the Fo–Fc Sigmaa weighted map and compati-
ble with the 2Fo–Fc Sigmaa weighted map. Simulated annealing (heating
up to 4000°K) using 1.7Å data was followed by conventional positional
and B-factor refinement. All rebuilding and graphic operations were done
with O and related Uppsala’s programs. At every stage, models resulting
from a refinement round were subjected to critical quality analyses, using
the programs O, OOPS [59], PROCHECK [60] and WHATIF [61,62]. 
The refined model
The current model contains two molecules each of 242 residues and
includes 417 ordered water molecules. Although the difference
between the two molecules in the asymmetric unit were carefully
watched during model building, refinements were done without non-
crystallographic restraints. Nevertheless, the rms deviation between the
Ca atoms of the two monomers in the asymmetric unit is only 0.267Å
(the average displacement is 0.196 Å). The quality of the refined
structure was assessed using the Biotech validation suite for Protein
structures [63]. All residues, except Leu217(220) of each monomer
are in the allowed regions of the Ramachandran diagram. Leu217(220)
due to its central position in a g-turn has unusual (f,ψ) parameters; the
electron density for this residue is well-defined (real space correlation
factor 0.934 and 0.937 for the two independent molecules) in the
(2Fo–Fc) cross-validated Sigmaa-weighted map. 
Accession numbers
The atomic coordinates have been deposited at the Brookhaven
Protein Data Bank with the code 1agj.
Note added in proof
An independent structure determination of the exfoliative toxin A, in
another space group at 2.1 Å resolution (Vath, G.M., et al., Ohlendorf,
D.H. (1997). The structure of the superantigen exfoliative toxin A
suggests a novel regulation as a serine protease. Biochemistry 36,
1559–1566), was published after our paper was submitted. As can be
judged from both papers, the two structures are similar.
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